How to buy Celldex Therapeutics stock - 08 March

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Celldex Therapeutics stock

Own Celldex Therapeutics stock in just a few minutes.


Fact checked

Celldex Therapeutics, Inc is a biotechnology business based in the US. Celldex Therapeutics shares (CLDX) are listed on the NASDAQ and all prices are listed in US Dollars. Celldex Therapeutics employs 127 staff and has a trailing 12-month revenue of around USD$4.5 million.

How to buy shares in Celldex Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Celldex Therapeutics. Find the stock by name or ticker symbol: CLDX. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Celldex Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Celldex Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Celldex Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Celldex Therapeutics share price

Use our graph to track the performance of CLDX stocks over time.

Celldex Therapeutics shares at a glance

Information last updated 2021-03-03.
52-week rangeUSD$1.5 - USD$30.17
50-day moving average USD$22.8368
200-day moving average USD$17.7946
Wall St. target priceUSD$34.33
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-3.741

Buy Celldex Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Gold/Commodities
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Stocks, Options, ETFs
Get two free stock valued between $2.50 and $250
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Stocks, Options, Cryptocurrency
Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg
Futures: $2.50/contract to open, $0 to close
Get 100 shares of stock (worth $1 to $6 a share)
Open and fund a new cash or margin account with $2,000+
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Interactive Brokers
Stocks, Bonds, Options
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Celldex Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Celldex Therapeutics financials

Revenue TTM USD$4.5 million
Gross profit TTM USD$-39,099,000
Return on assets TTM -16.76%
Return on equity TTM -29.17%
Profit margin 0%
Book value $5.813
Market capitalisation USD$1.1 billion

TTM: trailing 12 months

Shorting Celldex Therapeutics shares

There are currently 3.4 million Celldex Therapeutics shares held short by investors – that's known as Celldex Therapeutics's "short interest". This figure is 2.1% down from 3.5 million last month.

There are a few different ways that this level of interest in shorting Celldex Therapeutics shares can be evaluated.

Celldex Therapeutics's "short interest ratio" (SIR)

Celldex Therapeutics's "short interest ratio" (SIR) is the quantity of Celldex Therapeutics shares currently shorted divided by the average quantity of Celldex Therapeutics shares traded daily (recently around 609028.49557522). Celldex Therapeutics's SIR currently stands at 5.65. In other words for every 100,000 Celldex Therapeutics shares traded daily on the market, roughly 5650 shares are currently held short.

However Celldex Therapeutics's short interest can also be evaluated against the total number of Celldex Therapeutics shares, or, against the total number of tradable Celldex Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Celldex Therapeutics's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Celldex Therapeutics shares in existence, roughly 90 shares are currently held short) or 0.087% of the tradable shares (for every 100,000 tradable Celldex Therapeutics shares, roughly 87 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Celldex Therapeutics.

Find out more about how you can short Celldex Therapeutics stock.

Celldex Therapeutics share dividends

We're not expecting Celldex Therapeutics to pay a dividend over the next 12 months.

Have Celldex Therapeutics's shares ever split?

Celldex Therapeutics's shares were split on a 1:15 basis on 11 February 2019. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Celldex Therapeutics shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Celldex Therapeutics shares which in turn could have impacted Celldex Therapeutics's share price.

Celldex Therapeutics share price volatility

Over the last 12 months, Celldex Therapeutics's shares have ranged in value from as little as $1.5 up to $30.17. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Celldex Therapeutics's is 2.706. This would suggest that Celldex Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Celldex Therapeutics overview

Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of immunotherapies and other cancer-targeting biologics. It develops CDX-1140, an agonist human monoclonal antibody, which is being studied as a single-agent and in combination with CDX-301 in a Phase I dose-escalation study in metastatic solid tumors and B cell lymphomas; CDX-3379, a monoclonal antibody designed to block the activity of ErbB3 that is in an early Phase II study in advanced head and neck squamous cell cancer in combination with Erbitux; CDX-0159, a Phase I monoclonal antibody that binds the KIT receptor and inhibits its activity; and CDX-527, a bispecific antibody that uses anti-PD-L1 and CD27 human antibodies to couple CD27 co-stimulation with blockade of the PD-L1/PD-1 pathway. The company also holds exclusive rights to CDX-301 and CD40 ligand, which are immune modulating molecules that increase the numbers and activity of immune cells that control immune responses. Celldex Therapeutics, Inc. has research collaboration and license agreements with University of Southampton; Amgen Inc.; Yale University; and MedImmune, LLC. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site